Global 500

Rank
173
Previous Next

Pfizer

Global Pharmaceuticals Brands
A blister pack containing Neurontin anti-epileptic capsules, produced by Pfizer Inc., sits on a pharmacy counter in this arranged photograph in London, U.K., on Thursday, Dec. 29, 2016. The rapid pace of innovation among drugmakers may continue to be overshadowed by broader investment themes, such as the switch away from defensive stocks into more cyclical industries, during 2017, according to Bloomberg Intelligence. Photographer: Chris Ratcliffe/Bloomberg via Getty ImagesChris Ratcliffe — Bloomberg via Getty Images
  • Previous Rank
    186
  • Revenues ($M)
    52824
  • Revenue Percent Change
    8.1
  • Profits ($M)
    7215
  • Profits Percent Change
    3.7
  • Assets ($M)
    171615
  • Employees
    96500

Pfizer landed one of 2016’s most sought-after biopharma deals with its $14 billion acquisition of cancer drug maker Medivation, beating out the likes of Sanofi. In another critical business decision, the firm announced last fall that it wouldn’t split into two publicly traded companies in order to separate its generic and branded pharmaceutical businesses, raising the prospect of even more future deals. Pfizer also came under fire over drug price increases–including a record $107 million fine by U.K. regulators for hiking an epilepsy treatment’s price by 2,600%.

Company Information

CEOIan C. Read
SectorHealth Care
IndustryPharmaceuticals
HQ LocationNew York, NY
Websitewww.pfizer.com
Years on Global 500 List23
Employees96,500

Key Financials (Last Fiscal Year)

Revenues ($M)$52,824
Profits ($M)$7,215
Assets ($M)$171,615
Total Stockholder Equity ($M)$59,544

Profit Ratios

Profit as % of Revenues13.7%
Profits as % of Assets4.2%
Profits as % of Stockholder Equity12.1%